BioCurate and Takeda Renew Alliance to Accelerate Discoveries of New Drugs and Therapeutics




September 20 2023

Partnership enables collaboration in high-quality therapy development programs.

BioCurate, the independently-operated joint venture between The University of Melbourne and Monash University, today announced the renewal of its partnership with Takeda to identify and collaborate on projects to advance promising early stage therapeutic research.

The alliance increases each partner’s access to scientific and commercialisation expertise, as well as exposure to candidate projects in key therapeutic areas for collaboration, including potential for co-investment.

On selected projects, the two partners will work together to overcome the barriers to their translation and commercialisation, providing critical advice and expertise to streamline the therapeutic development process.

Dr. Eric Hayes, Director of Partnerships at BioCurate, said:

“We’re thrilled to renew our strategic alliance with Takeda, whose world-class team has a proven track record of successful collaborations to bring new, commercially viable medicines to market. We have some of the world’s best medical research teams operating out of Victoria’s laboratories; Takeda’s expertise will help ensure this research has the best possible chance of becoming therapies that improve people’s lives.”

Dr. Michael Martin, Head of Takeda’s Center for External Innovation said:

“Continuing our collaboration with BioCurate renews our bond with their internationally renowned team, and our connection with the thriving ‘Parkville Precinct’ medical research community. We look forward to identifying promising projects for collaboration, and jointly pursuing the potential to create transformational new therapies for patients.”

About BioCurate

BioCurate is a bold, collaborative venture, dedicated to delivering benefits to the community by helping to advance Australian research and innovation globally. Jointly formed by the University of Melbourne and Monash University, with support from the Victorian State Government, BioCurate identifies promising biomedical research discoveries and manages their translation into high quality pre-clinical candidates with the aim to develop potential novel human therapeutics.

We operate in the under-resourced, yet critical, early phases of therapeutic development to overcome common barriers to success and drive early decisions. BioCurate is operationally independent, with a team of experts that brings decades of scientific and commercial expertise, enabling us to recognise and realise real-world potential and providing a critical bridge between academia and industry.  Governance is provided by an experienced Board with an independent Board Chair, the Hon John Brumby AO, supported by Directors with specialist backgrounds in biotechnology, investment and corporate governance.